Reports Q3 revenue $2.0M vs. $0 last year. Cash and cash equivalents for the third quarter ended September 30, 2023 were $101.8M, expected to fund operations for at least the next 12 months based on management’s current operating plan. “The data generated to date reinforce our belief that denifanstat has the potential to treat patient populations in need across important therapeutic indications including NASH, oncology, and acne. Denifanstat, as a once-daily, oral pill, offers a convenient and well-tolerated potential treatment, particularly important for NASH, for which there are currently no approved treatments in the United States or Europe,” said CEO Dave Happel. “The Sagimet team remains focused on delivering week 52 topline results, including liver biopsy, from our Phase 2b FASCINATE-2 clinical trial in NASH in Q1 of next year, a crucial milestone in our clinical development of denifanstat.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SGMT:
- Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
- Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD – The Liver Meeting® 2023
- Sagimet presents preclinical results on FASN inhibitor, FASCINATE-2 data
- Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD – The Liver Meeting® 2023
- Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference